- $2.55bn
- $1.50bn
- $139.74m
Beam Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Axon Enterprise, RingCentral, Roblox
Beam Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Beam Therapeutics Reports Pipeline Updates And Q1 2023 Financial Results
Beam Therapeutics Inc expected to post a loss of $1.34 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Chart Industries, Nvidia, Seagen
U.S. RESEARCH ROUNDUP-Aptinyx, Eve Holding, Gossamer Bio
Beam Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Beam Therapeutics Reports Q4 Loss Of $0.54 Per Share
Beam Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview
Brief: Beam Therapeutics Reports Progress Across Base Editing Portfolio
U.S. STOCKS ON THE MOVE-Aurora, Boeing, Lockheed Martin
Beam Therapeutics rises as FDA lifts hold on cancer drug study
Brief: Beam Therapeutics Announces FDA Lifting Clinical Hold On IND Application For Beam-201
Brief: Beam Therapeutics Enrolls First Patient In Beacon Clinical Trial For The Treatment Of Sickle Cell Disease
U.S. RESEARCH ROUNDUP-Linkbancorp, Oyster Point Pharma, Viatris
U.S. RESEARCH ROUNDUP-Linkbancorp, Oyster Point Pharma, Viatris
U.S. STOCKS ON THE MOVE-Boeing, U.S. energy, Delek US
U.S. STOCKS ON THE MOVE-Kosmos Energy, Scisparc, Walgreens